Skip to main content

Table 3 Radiological response and pathological response

From: Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II–III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial

Radiological response (N=50)

 Complete response

8 (16.0%)

 Partial response

30 (60.0%)

 Stable disease

10 (20.0%)

 Progressive disease

2 (4.0%)

Pathological response (N=36)

 Non-MPR

16 (44.4%)

 MPR

20 (55.6%)

 CPR

10 (27.8%)

Downstaging of nodal status (N=36)

 N3 to N0

3 (8.3%)

 N2 to N1

2 (5.5%)

 N2 to N0

10 (27.8%)

 N1 to N0

8 (22.2%)